Maravai Lifesciences Stock Fair Value – MARAVAI LIFESCIENCES Reports Earnings Results for Second Quarter of Fiscal Year 2023

August 15, 2023

🌥️Earnings Overview

MARAVAI LIFESCIENCES ($NASDAQ:MRVI) reported total revenue of USD 68.9 million for the second quarter of fiscal year 2023, which was a 71.6% decrease from the same quarter of the previous year. Instead of the net income of USD 71.2 million recorded in the prior year, the company experienced a net loss of USD 6.5 million. This was reported on June 30, 2023.

Price History

The company’s stock opened at $11.4 and closed at $11.0, down 4.2% from the prior closing price of $11.5. This reflects the market’s reaction to MARAVAI LIFESCIENCES‘ financial results for the quarter. Despite the drop in the stock price, MARAVAI LIFESCIENCES has reported strong growth in its revenue, operating profit, and net income.

The company’s strong results are indicative of their ability to leverage their core competencies and expand into new markets. Going forward, investors will be looking for MARAVAI LIFESCIENCES to continue its strong performance and deliver further growth in revenue and profitability. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…

    Total Revenues Net Income Net Margin
    543.91 75.5 14.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…

    Operations Investing Financing
    458.75 -267.61 -187.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…

    Total Assets Total Liabilities Book Value Per Share
    2.32k 1.41k 3.95
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Maravai Lifesciences are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    83.4% 185.6% 41.2%
    FCF Margin ROE ROA
    80.3% 26.8% 6.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Maravai Lifesciences Stock Fair Value

    At GoodWhale, we have conducted a financial analysis of MARAVAI LIFESCIENCES and have concluded that the fair value of its share is around $21.9. This was calculated by our proprietary Valuation Line. Unfortunately, the current price of the share is only $11.0, meaning that MARAVAI LIFESCIENCES is currently undervalued by 49.8%. We encourage any investors looking at MARAVAI LIFESCIENCES to take this into consideration when making their decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.

    – Takara Bio Inc ($TSE:4974)

    Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.

    – Forward Pharma A/S ($NASDAQ:FWP)

    Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:

    Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.

    – Obio Technology (shanghai) Corp Ltd ($SHSE:688238)

    Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.


    MARAVAI LIFESCIENCES reported a significant decline in earnings for the second quarter of the 2023 fiscal year. Revenue dropped by 71.6%, leading to a net loss of USD 6.5 million, compared to 71.2 million in net income reported for the same quarter last year. This resulted in a decrease in the stock price of MARAVAI LIFESCIENCES on the same day.

    Investors should consider this news as a sign of a negative outlook for the company and may want to adjust their portfolios accordingly. Long-term investors may also take this opportunity to enter at discounted prices if they believe MARAVAI LIFESCIENCES has potential for recovery in the future.

    Recent Posts

    Leave a Comment